- Home
- FBNC vs KYMR Comparison
FBNC vs KYMR Comparison
Compare FBNC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- KYMR
- Stock Information
- Founded
- FBNC 1934
- KYMR 2015
- Country
- FBNC United States
- KYMR United States
- Employees
- FBNC N/A
- KYMR N/A
- Industry
- FBNC Major Banks
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- FBNC Finance
- KYMR Health Care
- Exchange
- FBNC Nasdaq
- KYMR Nasdaq
- Market Cap
- FBNC 1.7B
- KYMR 1.8B
- IPO Year
- FBNC N/A
- KYMR 2020
- Fundamental
- Price
- FBNC $40.69
- KYMR $38.67
- Analyst Decision
- FBNC Buy
- KYMR Buy
- Analyst Count
- FBNC 4
- KYMR 15
- Target Price
- FBNC $49.33
- KYMR $55.47
- AVG Volume (30 Days)
- FBNC 157.2K
- KYMR 650.3K
- Earning Date
- FBNC 07-23-2025
- KYMR 05-09-2025
- Dividend Yield
- FBNC 2.13%
- KYMR N/A
- EPS Growth
- FBNC N/A
- KYMR N/A
- EPS
- FBNC 2.11
- KYMR N/A
- Revenue
- FBNC $347,423,000.00
- KYMR $58,885,000.00
- Revenue This Year
- FBNC $35.04
- KYMR $32.80
- Revenue Next Year
- FBNC $6.91
- KYMR $8.88
- P/E Ratio
- FBNC $19.59
- KYMR N/A
- Revenue Growth
- FBNC N/A
- KYMR N/A
- 52 Week Low
- FBNC $29.53
- KYMR $19.45
- 52 Week High
- FBNC $50.34
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- FBNC 46.08
- KYMR 69.36
- Support Level
- FBNC $40.48
- KYMR $28.06
- Resistance Level
- FBNC $42.51
- KYMR $30.28
- Average True Range (ATR)
- FBNC 0.96
- KYMR 1.71
- MACD
- FBNC -0.22
- KYMR 0.42
- Stochastic Oscillator
- FBNC 5.59
- KYMR 76.72
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.